Skip to main content
editorial
. 2021 Jun 16;27:63. doi: 10.1186/s10020-021-00321-3

Fig. 9.

Fig. 9

a CAT Scans of the first patient to respond to treatment (in 2009) with adoptive transfer of autologous lymphocytes genetically engineered to express a chimeric antigen receptor targeting CD19 (left, lymphoma burden shown with arrows); right, complete cancer regression now ongoing over 10 years later. b In clinic with the first patient 10 years after treatment